Please provide your email address to receive an email when new articles are posted on . Individuals with moderate to severe obstructive sleep apnea had increased odds of having neovascular AMD.

Moderate to severe obstructive sleep apnea (OSA) independently correlated with development of cerebral microbleeds seen on brain MRI. Cerebral microbleeds are considered an early marker of cerebral ...

June 21 (Reuters) - Eli Lilly (LLY.N), opens new tab on Friday said its popular weight-loss drug Zepbound helped resolve moderate to severe obstructive sleep apnea in up to 52% of patients in two late ...

Averaging up to 20% of weight loss, adults taking Zepbound had at least 25 fewer breathing interruptions each hour as they slept Up to 50% of adults taking Zepbound no longer had symptoms associated ...

LONDON--(BUSINESS WIRE)--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced its OSPREY clinical study, Treating Obstructive Sleep Apnea Using Targeted ...

Triple fixed-dose regimens of an inhaled glucocorticoid, a long-acting muscarinic antagonist (LAMA), and a long-acting β 2-agonist (LABA) for chronic obstructive pulmonary disease (COPD) have been ...

Please provide your email address to receive an email when new articles are posted on . Zepbound demonstrated significantly more efficency than placebo in treating adults with OSA. The drug was also ...

The Food and Drug Administration (FDA) has approved Zepbound ® (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea (OSA) in adults with obesity. Zepbound is a dual ...

The first medication for obstructive sleep apnea has been approved by the U.S. Food and Drug Administration (FDA). On Dec. 20, the FDA announced that the agency has approved Eli Lilly's Zepbound ...

Moderate to severe obstructive sleep apnea (OSA) independently correlated with development of cerebral microbleeds seen on brain MRI that are linked to stroke and dementia risk, a longitudinal cohort ...